SY 009
Alternative Names: SY-009Latest Information Update: 28 Jun 2023
At a glance
- Originator Eli Lilly and Company
- Developer Yabao Pharmaceutical Group
- Class Antihyperglycaemics
- Mechanism of Action Sodium-glucose transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in China (PO, Tablet)
- 21 Jun 2022 Suzhou Yabao Pharmaceutical plans a phase II trial for Type 2 diabetes mellitus (In adults, In the elderly) in China (PO) (NCT05426018)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in China (PO, Capsule)